| Year |
Citation |
Score |
| 2021 |
Sagar S, Singh S, Mallareddy JR, Sonawane YA, Napoleon JV, Rana S, Contreras JI, Rajesh C, Ezell EL, Kizhake S, Garrison JC, Radhakrishnan P, Natarajan A. Structure activity relationship (SAR) study identifies a quinoxaline urea analog that modulates IKKβ phosphorylation for pancreatic cancer therapy. European Journal of Medicinal Chemistry. 222: 113579. PMID 34098465 DOI: 10.1016/j.ejmech.2021.113579 |
0.506 |
|
| 2020 |
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, et al. Correction: Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 11: 2462-2463. PMID 32637035 DOI: 10.18632/Oncotarget.27403 |
0.743 |
|
| 2020 |
Rana S, Kour S, Sonawane YA, Robb CM, Contreras JI, Kizhake S, Zahid M, Karpf AR, Natarajan A. Symbiotic Prodrugs (SymProDs) Dual Targeting of NFkappaB and CDK. Chemical Biology & Drug Design. PMID 32237047 DOI: 10.1111/Cbdd.13684 |
0.781 |
|
| 2019 |
Kour S, Rana S, Contreras JI, King HM, Robb CM, Sonawane YA, Bendjennat M, Crawford AJ, Barger CJ, Kizhake S, Luo X, Hollingsworth MA, Natarajan A. CDK5 Inhibitor Downregulates Mcl-1 and Sensitizes Pancreatic Cancer Cell Lines to Navitoclax. Molecular Pharmacology. 96: 419-429. PMID 31467029 DOI: 10.1124/Mol.119.116855 |
0.769 |
|
| 2018 |
Contreras JI, Robb CM, King HM, Baxter J, Crawford AJ, Kour S, Kizhake S, Sonawane YA, Rana S, Hollingsworth MA, Luo X, Natarajan A. Chemical Genetic Screens Identify Kinase Inhibitor Combinations that Target Anti-Apoptotic Proteins for Cancer Therapy. Acs Chemical Biology. PMID 29608269 DOI: 10.1021/Acschembio.8B00077 |
0.757 |
|
| 2018 |
Robb CM, Kour S, Contreras JI, Agarwal E, Barger CJ, Rana S, Sonawane Y, Neilsen BK, Taylor M, Kizhake S, Thakare RN, Chowdhury S, Wang J, Black JD, Hollingsworth MA, et al. Characterization of CDK(5) inhibitor, 20-223 (aka CP668863) for colorectal cancer therapy. Oncotarget. 9: 5216-5232. PMID 29435174 DOI: 10.18632/Oncotarget.23749 |
0.787 |
|
| 2017 |
Robb CM, Contreras JI, Kour S, Taylor MA, Abid M, Sonawane YA, Zahid M, Murry DJ, Natarajan A, Rana S. Chemically induced degradation of CDK9 by a proteolysis targeting chimera (PROTAC). Chemical Communications (Cambridge, England). PMID 28636052 DOI: 10.1039/C7Cc03879H |
0.753 |
|
| 2017 |
Yefidoff-Freedman R, Fan J, Yan L, Zhang Q, Dos Santos GRRM, Rana S, Contreras JI, Sahoo R, Wan D, Yang J, Dias-Teixeira KL, Morisseau C, Du R, Halperin JA, Hammock BD, et al. Development of 1-((1,4-trans)-4-aryloxycyclohexyl)-3-arylurea Activators of the Heme Regulated Inhibitor as Selective Activators of Eucaryotic Translation Initiation Factor 2 Alpha (eIF2α) Phosphorylation Arm of the Integrated Endoplasmic Reticulum Stress Response. Journal of Medicinal Chemistry. PMID 28590739 DOI: 10.1021/Acs.Jmedchem.7B00059 |
0.686 |
|
| 2017 |
Arnst JL, Hein AL, Taylor MA, Palermo NY, Contreras JI, Sonawane YA, Wahl AO, Ouellette MM, Natarajan A, Yan Y. Discovery and characterization of small molecule Rac1 inhibitors. Oncotarget. PMID 28410221 DOI: 10.18632/Oncotarget.16656 |
0.786 |
|
| 2016 |
Sonawane YA, Taylor MA, Napoleon JV, Rana S, Contreras JI, Natarajan A. Cyclin dependent kinase 9 inhibitors for cancer therapy. Journal of Medicinal Chemistry. PMID 27171036 DOI: 10.1021/Acs.Jmedchem.6B00150 |
0.843 |
|
| 2016 |
Rana S, Blowers EC, Tebbe C, Contreras JI, Radhakrishnan P, Kizhake S, Zhou T, Rajule RN, Arnst J, Munkarah AR, Rattan R, Natarajan A. Isatin derived spirocyclic analogs with α-methylene-γ-butyrolactone as anticancer agents: A structure activity rela-tionship study. Journal of Medicinal Chemistry. PMID 27077228 DOI: 10.1021/Acs.Jmedchem.6B00400 |
0.738 |
|
| Show low-probability matches. |